Table of Contents
Independent clinical laboratory industry has experienced less than 20 years’ development in China, but there were more than 110 independent clinical laboratories in China with rapid development. Kingmed, Adicon and Dian placed on the top three respectively among large-scale chain-store clinical laboratories. Market scale was approximately CNY 2.5 billion in 2012, only accounting for about 1.5% of market shares in clinical laboratory industry currently. But in America, independent clinical laboratory industry accounted for one third of market shares, so there is still a big gap when compared with America. Huidian Research takes a view that sales value of Kingmed firstly broke through CNY 1 billion as of 2012, which can be deemed as China independent clinical laboratory industry entered rapid-growth period.
Under the background of new medical reform, independent clinical laboratory industry will further expand so as to enter rapid-growth period. During this period, increasing new entrants will step into this industry, chain enterprises and solo independent laboratory will coexist. But in the long run, chain enterprises are equipped with the capacities of large-scale purchase and standard management and administration for reducing production costs; service network layout will obtain brand effect for attracting customers. However, the service of solo independent laboratory is limited within 400 kilometers, customer resources are inclined to be saturated. In addition, it will drop out the market along with losses because of declined prices. Thus chain enterprises are expected to be still prosperous.
Through comparing testing project reserves, layout of service network station and management and administration capability in domestic chain enterprises, Huidian Research holds a view of Kingmed owns absolute competitive advantages and will keep its leading position in industry due to high-end project reserves and many laboratories are widely distributed; Adicon and Dian placed on the second, Adicon has high-end project reserves and strict quality control standards, while Dian owns differentiation competitive advantages such as level-to-level administration laboratories, increase output and “ agency + service ” mode for reducing purchasing costs etc.; DAAN Gene started late (2007), so it is slightly inferior to the other three enterprises.
“Research and Development Trend of China Independent Clinical Laboratory Market, 2013-2017” mainly conducts an in-depth market research on development environment and market status quo of China independent clinical laboratory industry, makes an analysis of domestic market status quo, supply and demand, upstream and downstream industries and business performance of key enterprises, meanwhile makes a forecast for the industry so as to provide a decision-making reference for enterprises to understand and invest such industry.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Complete report $34,500. DataPack (test volumes, sales forecasts, supplier shares) $21,100. The report is available by country, section, market segment, and can be custom-tailored to your specific ...
Complete report $19,700. DataPack (test volumes, sales forecasts, supplier shares) $12,800. The report is available by country, section, market segment, and can be custom-tailored to your specific ...
The global healthcare IT market is expected to grow at a CAGR of 15.9% from 2016 to 2021 and reach USD 280.25 billion. Growing need to manage regulatory compliance through healthcare IT solutions, government ...